- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 15, Issue 2, 2014
Current Drug Targets - Volume 15, Issue 2, 2014
Volume 15, Issue 2, 2014
-
-
The First Approved Agent in the Glitazar’s Class: Saroglitazar
More LessThe new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller G Read More
-
-
-
Communication Factors-Promising Targets in Osteoporosis Treatment
Authors: Yan Zhang, Peijun Liu, Juan Li, Kun Li, Yue Teng, Xiang Wang and Xu LiOsteoporosis is one of the most serious under-diagnosed and under-treated recessive diseases, leading to increased mortality and morbidity as well as huge economic burden. The fundamental reason for the occurrence of osteoporosis lies in the disequilibrium between bone resorption mediated by osteoclasts and bone formation mediated by osteoblasts. Osteoclast-osteoblast communication plays important roles in the maintena Read More
-
-
-
Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Authors: Gustavo H. Oliveira-Paula, Riccardo Lacchini and Jose E. Tanus-SantosNitric oxide (NO) is an important vasodilator produced by vascular endothelium. Its enzymatic formation is derived from three different synthases: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS) synthases. While relatively small amounts of NO produced by eNOS are important to cardiovascular homeostasis, high NO levels produced associated with iNOS activity may have detrimental consequences to the cardiova Read More
-
-
-
The Medicinal Potential of Natural Products for the Development of Anti- Influenza Agents
Authors: Fudong Sun and Ruiqin HuangInfluenza neuraminidase (NA) is an important target for designing anti-influenza drugs. By now, three inhibitors, zanamivir, oseltamivir and peramivir have been approved. However, in recent years, the potential threat of influenza pandemics and constant emergence of new drug-resistant influenza virus strains have weaken the defensive role of the current anti-influenza drugs. From another point of view, in this re Read More
-
-
-
A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Authors: Karunanidhi Priyanka and Sanjay SinghAdministration of drugs through skin via transdermal route is a non-invasive approach and applicable for systemic delivery but it is not suitable for drugs having higher molecular weight. Various approaches have been used to improve the efficacy of transdermal route such as vesicular system, iontophoresis, microneedles, use of permeation enhancers, etc. Among the several approaches, vesicular delivery is gaining importance Read More
-
-
-
Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Authors: Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. MacaulayVenous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imagin Read More
-
-
-
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Authors: Arunachalam Muthuraman, Nirmal Singh, Amteshwar Singh Jaggi and Muthusamy RameshUnderstanding mechanism of neuropathic pain is too complex and involves both peripheral and central pathophysiological phenomenon. Accordingly the treatment of neuropathic pain is also very complex and is unsatisfactory. The present review attempts to discuss the currently employed pharmacological agents for the management of neuropathic pain including anti-depressants, anti-convulsants, NMDA recepto Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
